Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2023	Dec 31, 2022
Revenue Revenue Growth	0.01	0.01	0.69
Revenue Growth	-	-98.12%	-
Gross Profit Gross Profit Growth	-	-	0.09
Operating Income Operating Income Growth	-35.27	-35.27	-37.5
Net Income Net Income Growth	-48.07	-48.07	-38.01
Earnings Per Share EPS Growth	-7.99	-7.99	-13.13
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2023	Dec 31, 2022
Cash & Investments Cash & Investments Growth	4.88	4.88	2.41
Total Debt Total Debt Growth	8.32	8.32	1.75
Net Cash (Debt) Net Cash Growth	-3.43	-3.43	0.66
Net Cash Growth	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-0.57	-0.57	0.23

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2023	Dec 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-29.49	-29.49	-34.51
Free Cash Flow Free Cash Flow Growth	-29.49	-29.49	-34.51
Free Cash Flow Growth	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2023	Dec 31, 2022
Gross Margin	-	-	13.01%
Operating Margin	-271276.92%	-271276.92%	-5419.51%
Pretax Margin	-399876.92%	-399876.92%	-5408.82%
Profit Margin	-369784.61%	-369784.61%	-5493.21%

Valuation

Chart

Fiscal Year	Current	FY 2023	FY 2022
Period Ending	Jul 28, 2026	Dec 31, 2023	Dec 31, 2022
PS Ratio	2753.34	610.40	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2023

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jan 31, 2026

Data Sources Report a data error